Total: 4 |
|
PMID (PMCID) | ||
---|---|---|
29094253 |
FEMALE | Adult |
Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review. | ||
Harao M, Ando J, Kamata H, Hoshi N, Igarashi S, Sekiguchi R, Sugano K. Breast Cancer. 2018;25(2):243-249. |
||
Peritoneal carcinoma can occur in association with hereditary breast and ovarian cancer syndrome, which is thought to account for 5-6% of all breast cancer. | ||
28049106 |
FEMALE | Middle Aged |
Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report. | ||
de Jonge MM, Mooyaart AL, Vreeswijk MP, de Kroon CD, van Wezel T, van Asperen CJ, Smit VT, Dekkers OM, Bosse T. Eur J Cancer. 2017;72:215-225. |
||
As high-grade ovarian tubal serous carcinoma is known to be associated with BRCA1/2 pathogenic germline mutations (PMs), we aimed to explore whether USC is also a constituent of hereditary breast and ovarian cancer syndrome. | ||
24719479 |
FEMALE | Middle Aged |
Serous tubal intraepithelial carcinoma in a Japanese woman with a deleterious BRCA1 mutation. | ||
Ishikawa H, Kiyokawa T, Utsuno E, Matsushita K, Nomura F, Shozu M. Jpn J Clin Oncol. 2014;44(6):597-601. |
||
Here, we report the first case of serous tubal intraepithelial carcinoma identified through a risk-reducing salpingo-oophorectomy in a Japanese woman with hereditary breast and ovarian cancer syndrome and who had a deleterious germline mutation of E1214X in BRCA1, but not a BRCA2 mutation. | ||
24719479 |
FEMALE | Middle Aged |
Serous tubal intraepithelial carcinoma in a Japanese woman with a deleterious BRCA1 mutation. | ||
Ishikawa H, Kiyokawa T, Utsuno E, Matsushita K, Nomura F, Shozu M. Jpn J Clin Oncol. 2014;44(6):597-601. |
||
Our case demonstrated that risk-reducing salpingo-oophorectomy can detect occult cancers, including serous tubal intraepithelial carcinoma, thereby preventing future cancer development in the Japanese hereditary breast and ovarian cancer syndrome population. |